Comparative Study of Additive IOP Lowering Effects and Safety Profile of Ripasudil 0.4% Combined with Timolol 0.5% and Ripasudil 0.4% Combined with Bimatoprost 0.03% In Primary Open Angle Glaucoma in Indian Eyes
International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 2 | Views: 226 | Weekly Hits: ⮙2 | Monthly Hits: ⮙2

Comparative Studies | Ophthalmology | India | Volume 12 Issue 12, December 2023 | Popularity: 5.2 / 10


     

Comparative Study of Additive IOP Lowering Effects and Safety Profile of Ripasudil 0.4% Combined with Timolol 0.5% and Ripasudil 0.4% Combined with Bimatoprost 0.03% In Primary Open Angle Glaucoma in Indian Eyes

Nidhi Singh, Jimmy Mittal, Abhishek Singh, Niharika, Alok Ranjan, Alok Kumar Singh


Abstract: Introduction: IOP lowering is the mainstay of glaucoma treatment. Beta-adrenergic drugs and prostaglandins are some of the commonly used topical medications for this purpose. Ripasudil hydrochloride hydrate, a new Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor has also emerged as an effective alternative, however, its efficacy as adjuvant to currently used topical medications has not been studied. Aim: To study additive IOP lowering effects and safety profile of the rho-kinase inhibitor (Ripasudil) combined with Timolol or Bimatoprost in Primary Open Angle Glaucoma (POAG). Materials and Methods: A total of 80 POAG patients were allocated to four study groups ? TM (n=20) receiving topical 0.5% Timolol, TMR (n=20) 0.5% Timolol + 0.4% Ripusadil, BP (n=20) receiving topical 0.03% Bimatoprost and BPR (n=20) ? 0.03% Bimatoprost + 0.4% Ripusadil. Change in IOP from baseline was measured at 4, 6 and 8 week follow-ups. Result: At last follow-up, mean decline in IOP as compared to baseline was 6.21?1.56, 8.44?1.55, 6.08?1.54 and 8.74?1.53 mmHg respectively in TM, TMR, BP and BPR groups respectively (p<0.001). No major adverse effect was seen in any study group. Conclusion: Addition of Ripusadil to conventionally used topical hypotensive agents added to their IOP lowering efficacy without additional burden of adverse effects.


Keywords: Ripusadil, Primary open angle glaucoma (POAG), Prostaglandin, Beta-adrenergic


Edition: Volume 12 Issue 12, December 2023


Pages: 748 - 751


DOI: https://www.doi.org/10.21275/SR231206212100



Make Sure to Disable the Pop-Up Blocker of Web Browser


Text copied to Clipboard!
Nidhi Singh, Jimmy Mittal, Abhishek Singh, Niharika, Alok Ranjan, Alok Kumar Singh, "Comparative Study of Additive IOP Lowering Effects and Safety Profile of Ripasudil 0.4% Combined with Timolol 0.5% and Ripasudil 0.4% Combined with Bimatoprost 0.03% In Primary Open Angle Glaucoma in Indian Eyes", International Journal of Science and Research (IJSR), Volume 12 Issue 12, December 2023, pp. 748-751, https://www.ijsr.net/getabstract.php?paperid=SR231206212100, DOI: https://www.doi.org/10.21275/SR231206212100